Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Incannex Healthcare (IXHL) EBIT (2023 - 2025)

Incannex Healthcare's EBIT history spans 3 years, with the latest figure at -$7.0 million for Q4 2025.

  • For Q4 2025, EBIT fell 39.79% year-over-year to -$7.0 million; the TTM value through Dec 2025 reached -$26.3 million, up 7.4%, while the annual FY2025 figure was -$23.8 million, 20.81% up from the prior year.
  • EBIT for Q4 2025 was -$7.0 million at Incannex Healthcare, down from -$6.8 million in the prior quarter.
  • Across five years, EBIT topped out at -$4.9 million in Q3 2023 and bottomed at -$9.7 million in Q2 2024.
  • The 3-year median for EBIT is -$6.9 million (2025), against an average of -$6.8 million.
  • The largest annual shift saw EBIT surged 37.32% in 2024 before it crashed 39.79% in 2025.
  • A 3-year view of EBIT shows it stood at -$8.0 million in 2023, then soared by 37.32% to -$5.0 million in 2024, then tumbled by 39.79% to -$7.0 million in 2025.
  • Per Business Quant, the three most recent readings for IXHL's EBIT are -$7.0 million (Q4 2025), -$6.8 million (Q3 2025), and -$7.5 million (Q2 2025).